Q3 2025 Outlook Report | Evaluate
Explore the market catalysts driven by 23 drugs, devices, diagnostics, and deals anticipated in Q2 2025.| Evaluate
Explore the market catalysts driven by 23 drugs, devices, diagnostics, and deals anticipated in Q2 2025.| Evaluate
Explore Evaluate’s Q2 2025 biopharma report for the latest insights on M&A, IPOs, venture funding, and China’s rising influence. Essential reading for pharma, biotech, and pharma investors.| Evaluate
BIO International 2025 highlights, including trends in biotech investment, M&A activity, licensing, and the role of China in global biopharma. Download now for expert commentary, market statistics, and strategic guidance.| Evaluate
Discover key insights from Evaluate’s World Preview 2025 infographic, including GLP-1 growth, China’s biotech ascent, and looming patent expiries. Download now.| Evaluate
Pharma market growth forecasts and drug sales to 2030 reflect solid underlying demand. But much is changing across the biopharma landscape.| Evaluate
Drug sales to hit $1.75T by 2030, led by GLP-1s and China’s biotech rise amid global pharma shifts.| Evaluate
Discover the top 15 market catalysts in Q2 2025 across drugs, devices, diagnostics, and deals.| Evaluate
Biotechs sponsor a growing share of new drugs & many are commercializing their products too. What are the steps to successful biotech commercialization?| Evaluate
.Prepare for the patent cliff's impact on sales. This expert report from J+D Forecasting explores market shifts and forecasting strategies.| Evaluate
The oldest hub-and-spokes pharma companies are over 10 years old – has the portfolio biotech model been validated?| Evaluate
